Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial

BACKGROUND: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels, resulted in significantly lower moderate/severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabe, Klaus F., Martinez, Fernando J., Singh, Dave, Trivedi, Roopa, Jenkins, Martin, Darken, Patrick, Aurivillius, Magnus, Dorinsky, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392797/
https://www.ncbi.nlm.nih.gov/pubmed/34428980
http://dx.doi.org/10.1177/17534666211034329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392797/
https://www.ncbi.nlm.nih.gov/pubmed/34428980
http://dx.doi.org/10.1177/17534666211034329

Ejemplares similares